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constraints were violated we re-checked correspondence of 
the structures to the delineation standards of the Lungtech 
protocol. Association of violations and the prospectively 
recorded toxicity was evaluated. 
 
Results: According to DVHs 111 SBRT plans did not violate 
any of the dose constraints requested in the Lungtech trial. 
For 7/100 patients SBRT plans exceeded the Lungtech dose 
constraint for the proximal bronchial tree of EqD2=74.8Gy to 
> 0.5cc, one of them additionally for the esophagus of 
EqD2=64 Gy. 6/7 patients showed an increase in dyspnea, 2 
of them died 3 and 9 months after SBRT, one after 
hemoptysis and subsequent pneumonia, the other after being 
hospitalized for unclear progressive dyspnea; in both cases 
association of G5 toxicity to SBRT cannot be excluded. 
 
Conclusion: Despite the lack of detailed specific constraints 
within the STRIPE trial OAR exposure did not largely differ 
from current practice in modern SBRT. However, these 
preliminary results underline the importance of the dose 
constraints for the main airways within the Lungtech trial and 
the necessity to continuously review and adjust treatment 
procedures to upcoming evidence, especially when employing 
new techniques. 
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Purpose or Objective: SABR for primary NSCLC is becoming 
increasingly popular as evidence is mounting for its 
equivalent long-term clinical outcomes and good overall 
tolerability. We review our toxicity against dosimetry and 
achievement of dose constraints (SABR UK Consortium). We 
suggest that dosimetric constraints alone cannot be used to 
prevent SABR related side effects. 
 
Material and Methods: Patients with stage I NSCLC treated 
with SABR between January 2014 and August 2015 were 
included in this single centre cohort study. They were 
planned using relaxed breathing 4D CT then treated using 
VMAT. Baseline and dosimetric data was retrospectively 
collected by a clinical oncologist or physicist from the 
radiotherapy records. Patients were followed up at 4 weeks 
then at 3 monthly intervals until 1 year. CT scans were 
performed 3 and 12 months post radiotherapy. Prospective 
data collection was performed at follow up visits for clinical 
outcomes and acute and late normal tissue toxicity (scored 
using CTCAE v 3.0). 
 
Results: 28 patients were included in the study with a 
median follow up of 10.4 months. 19 patients have attended 
for post radiotherapy CT scans with 84.2% showing 
radiological response as per RECIST. All patients were 
assessed for acute toxicity data, 3.5% (1/28) noted grade 2 
reaction. Data on late toxicity was available for 19 patients: 
26.3% (5/19) experienced grade 2-3, no grade 4 or 5 reactions 
were recorded. When adjusted for baseline function (late 
toxicity score minus baseline score) this fell to 15% (3/19). 
Other than chest wall (CW) tolerances all dosimetry criteria 
were met. 10.7% of plans exceeded tolerance to 30cc CW 
(>30/32) with no recorded episodes of ≥grade 2 CW pain in 
these patients. 71.4% of plans exceeded dose constraint to 
0.01cc CW (>37/39) only 5% (1/20) complained of CW pain. 
Dosimetric analysis for this patient revealed dose to 30cc of 
CW was 25.8 Gy (<32), dose to 0.01 cc of CW was 59.1 Gy 
(<39), volume of PTV and CW overlapping was 0.03 cc and % 
of PTV-CW overlapping was 0.21%. 
 
Conclusion: We are achieving low rates of moderate or 
severe toxicity. Despite achieving dose constraints, a small 
cohort of patients developed toxicity grade 2-3. We 
hypothesize that these patients could develop radiotherapy 
toxicity due to other idiosyncratic factors (genetic 
polymorphisms, microenvironment). Further studies are 
currently running to investigate other causative factors. 
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Purpose or Objective: The aim of this study is to evaluate 
efficacy and toxicity of stereotactic body radiation therapy in 
early stage medically inoperable non-small lung cancer. 
 
Material and Methods: Data from patients affected by 
medically inoperable stage I NSCLC treated with stereotactic 
body radiation therapy (SBRT) were prospectively recorded. 
Treatments were planned employing 4D-CT . The prescribed 
dose was modulated according to location of the lesion and 
tolerance of the surrounding organs at risk: 54 Gy in 3 
fractions for peripheral lesions, 60 Gy in 4 fractions for 
lesions adjacent to the chest wall, 60 Gy in 8 fractions for 
central lesions. The primary endpoints were local control and 
toxicity, secondary endpoint was survival. The follow-up 
examinations were performed with CT and/or PET-CT at 1, 3, 
6, 9 and 12 months after treatment and every 6 months 
subsequentely. Acute and late side effects were recorded 
according to RTOG morbidity Scoring Scale.  
 
Results: From 2009 to 2014, 65 patients were treated. Mean 
patients’ age was 74 years (range 62-86). The lesions had a 
mean maximum diameter of 20 mm (range 10-36). All but 
seven patients were staged by PET-CT. 83% of cases lung 
cancer was histologically proven: 34 cases were 
adenocarcinoma, 15 squamous cell carcinomas, 5 
undifferentiated carcinomas. In the last 11 patients biopsy 
was not performed because of high risk features for 
complications and/or patient’s refusal. In this last group 81% 
had a positive PET-CT and lesion growth documented at 
subsequent CT and just two patients had only lesion growth. 
Lesion’s location were as follow: RUL 25/65 (38%), RML 2/65 
(3%), RIL 7/65 (11%), LUL 22/65 (34%) and LIL 9/65 (14%). 
Median follow-up in 61 evaluable patients was 40 months. 
Five local failure (8%) were recorded at a mean of 11,5 
months from the end of treatment (range 5.3-22). PET-CT 
SUV was the only parameter predictive for local failure, with 
a mean value of 14,2 in the recurrence group versus 6,1 in 
the recurrence-free group, respectively; p=0.03. Local 
control at 1 and 2 years were 89.6% and 86%. Median DFS was 
22.2 months and 1y-, 2y- and 3y- DFS were 66%, 47% and 40%, 
respectively. Lesions’ location according to treatment group 
was related to distant progression, which was significantly 
higher in peripheral location (p=0.004). Overall survival at 1y-
, 2y- and 3y were 97%, 77% and 66%, respectively. Treatment 
was well tolerated. G1 asymptomatic pulmonary toxicity was 
observed in 18% of cases (11/61), G2 pulmonary toxicity was 
recorded in 3% of patients. There were no pulmonary toxicity 
grade 3-4. No other toxicities were reported. 
 
Conclusion: SBRT is an effective and safe treatment for 
patients with medically inoperable stage I NSCLC. Local 
recurrence predictive value of PET-CT SUV could be 
investigated in bigger series. 
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Purpose or Objective: Radiation therapy in the palliation of 
intra-thoracic symptoms from locally advanced non-small cell 
lung cancer (NSCLC) is a significant component of workload in 
most radiotherapy departments. While most trials have 
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concentrated on optimizing dose schedules, we proposed a 
study demonstrating that using more technically advanced 
techniques would result in equivalent symptomatic relief and 
reduce symptomatic oesophagitis. 
 
Material and Methods: Thirty-five patients with symptomatic 
locally advanced or metastatic NSCLC were treated using a 
three-dimensional conformal technique and standardized 
dose regimens of 39Gy in 13 fractions, 20Gy in 5 fractions or 
17Gy in 2 fractions. Treatment plans sought to minimize 
oesophageal dose and oesophagitis was recorded during and 
at one month and three months following radiation therapy 
where applicable. Mean dose to the irradiated oesophagus 
was calculated for all treatment plans. 
 
Results: At follow-up of one month after therapy for all 
patients accrued, there were no grade three or higher 
oesophageal symptoms of oesophagitis or dysphagia reported. 
Four patients (11.4%) had experienced grade 2 toxicity. All 
patients in the study derived clinical benefit from the 
radiation therapy course. 
 
Conclusion: Use of three-dimensional conformal radiation 
techniques is widely practiced for treating intra-thoracic 
symptoms in the setting of NSCLC, however no direct study 
exists proving its superiority in reducing toxicity. This trial is 
the first of its kind showing that such techniques do provide 
patients with lower rates of oesophageal toxicity whilst 
yielding acceptable rates of symptom control. (Sponsored by 
the All-Ireland Cooperative Oncology Research Group 
(ICORG). Trial registration number 06-34) 
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Purpose or Objective: Although there is no standard 
treatment for postoperative recurrence of non-small-cell lung 
cancer (NSCLC), radiotherapy is occasionally used in the 
treatment of loco-regional recurrences. The objective of this 
study is to analyze clinical results of curative intent 
radiotherapy for loco-regional recurrence of NSCLC after 
complete surgical resection. 
 
Material and Methods: A total of 38 patients, who had 
developed loco-regional recurrence after complete resection 
and received curative intent radiotherapy between 1999 and 
2014, were retrospectively analyzed. There were 29 male 
patients and 9 female patients. The age range was 47-89 
years (median 70 years). 25 patients had adenocarcinoma, 
thirteen patients squamous cell carcinoma. There were 29 
patients with regional lymph nodes recurrence, and 10 
patients with local recurrence at primary or anastomotic sites 
with or without lymph nodes recurrence. No patient had 
distant metastasis at presentation. The clinical endpoints 
included overall survival, progression-free survival, loco-
regional recurrence within the irradiated field, and any other 
recurrence. The overall survival and local control rate were 
calculated from the day of radiotherapy completion and 
estimated by Kaplan-Meier method. 
 
Results: The median total dose of radiotherapy was 60 Gy 
(range, 50–70 Gy). Thirteen of the 38 patients were treated 
with concurrent chemotherapy. The median follow-up time 
after radiotherapy was 30.4 (2.9–151) months. 1–5-year 
survival rates were 81.2, 69.6, 55.7, 48.5 and 39.6%, 
respectively. The 5-year progression-free survival, and local 
control rate were 32.6%, and 67.6%, respectively. Eight 
patients have survived more than 5 years. There was no 
significant difference between patients with lymph nodes 
recurrence and those with local recurrence in overall 
survival. 
 
Conclusion: Radiation therapy for loco-regional recurrence 
after complete resection provides acceptable disease 
control. Curative intent radiation therapy can be the 
treatment of choice if no evidence of metastasis is observed. 
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Purpose or Objective: To determine predictive factors of 
local recurrence (LR) after Stereotactic Body Radiotherapy 
(SBRT). 
 
Material and Methods: Data were retrospectively analyzed 
from 136 consecutive patients and 156 lung tumors treated 
with curative intent SBRT between April 2012 and December 
2014 at our institution. Most patients had early lung cancer 
(76%). SBRT was also included in the treatment strategy for 
locally advanced (3%) or oligometastatic (21%) patients with 
an intent to complete response. 
 
Results: The median follow-up was 21.8 months (2.4-70.8 
months). The median age at diagnosis was 66,5 years (33-89 
years) and median performance status was 0,5 (range 1-3). 
54% patients had a smoking history with a median VEMS of 
62,2%. Histological confirmation was obtained in 67%: 35% 
adenocarcinoma, 21% squamous cell carcinoma, 5% 
undifferenciated NSCLC and 5% other. Molecular markers 
were known in 27 tumors (17%): negative markers in 10%, 
KRAS mutation in 6%, other in 2%. Tumor location was central 
in 28%, peripheral in 48%, and intermediate in 24%. Median 
SUVmax at diagnosis was 7,1. Median ITV was 31,7 cc (0,56-
104,8 cc) and median Biological effective dose (BED) was 
123,8 Gy (72-151,2 Gy, α/β=10). 11 LR occurred resulting in a 
2 year LR rate of 8% [CI 95%: 3-14%]; median: not reached; 
mean time to LR: 38.4 month [CI 95%: 36-39.6]. BED ≤100Gy 
(HR=5 [CI 95%: 1.1-22]; p=0.03), and Internal Target Volume 
(ITV) ≥20cc (HR=4.9 [CI 95%: 1.3 -18.5); p=0.02) were 
associated with a decreased LR in the multivariate analysis 
(MVA). Histology (squamous cell carcinoma), central location, 
and SUVmax of the treated lesion > 8 were not associated 
with local control in the MVA. Delay from diagnosis to SABR 
and molecular markers were not correlated with LR results in 
the univariate analysis. Two years overall survival and 
progression free survival rates were respectively 74% (IC 95%: 
65-83%) and 62% (IC 95%: 52-72%). 
 
Conclusion: BED should carefully be taken into account, 
particularly in case of tumors that exceed 20 cc 
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Purpose or Objective: It is unknown whether dose-response 
for the primary tumor is different from that of the involved 
lymph nodes (LN). As the recurrence rate is much lower in 
LN, we hypothesized that involved LN need a lower radiation 
dose than the primary tumor. 
